FDA clearance tops March glaucoma coverage
Click Here to Manage Email Alerts
FDA clearance for an additional Omni surgical system indication and the potential to delay treatment in patients with early glaucoma led glaucoma coverage in March.
Read the recent top glaucoma stories on Healio/OSN below.
Omni receives FDA clearance for additional indication
The FDA has granted 510(k) clearance to the Omni surgical system for canaloplasty followed by trabeculotomy to reduce IOP in primary open-angle glaucoma, according to a press release from Sight Sciences. Read more.
Treatment may be delayed for patients with early glaucoma
If glaucoma is diagnosed early, treatment for the disease can be delayed, as the treatment effect is usually modest and the patient has time to be treated at a later point. Read more.
Gold standard for IOP measurement possible during pandemic, but alternatives available
Goldmann applanation tonometry for IOP measurement is still possible during the SARS-CoV-2 pandemic with additional steps for safety, but alternative IOP measurement devices are gaining in popularity. Read more.
OCT reading centers may reduce unnecessary glaucoma specialist referrals
Interpretation of OCT images by an OCT reading center may successfully reduce the number of unnecessary glaucoma specialist referrals while also maintaining a high level of quality comparable with other screening strategies. Read more.
MIGS use increased twofold from 2013 to 2018
The use of minimally invasive glaucoma surgery in the U.S. increased twofold, with a gradual decrease in the use of standard procedures, from 2013 to 2018, according to the IRIS Registry. Read more.
Collapse
Read more about
Click Here to Manage Email Alerts